US adult treatment guidelines updated (May 2014)
27 May 2014. Related: Guidelines.
2014
US PrEP guidelines (May 2014): emphasis on broad access may miss optimal use by people at highest risk
27 May 2014. Related: Guidelines.
Incidence of HIV dual infections in US men who have sex with men
27 May 2014. Related: Basic science and immunology.
Reassessing the role of HDAC inhibitors in cure research
27 May 2014. Related: Cure-related research, Basic science and immunology.
More on the links between the CD4/CD8 ratio, immunological perturbations, and risk of illness and death
27 May 2014. Related: Cure-related research, Basic science and immunology.
EMA fast-track sofosbuvir/ledipasvir FDC for hepatitis C
27 May 2014. Related: Hepatitis coinfection.
Partner 2 study extended for gay couples
27 May 2014. Related: Other news.
TAILoR Study: telmisartan to reduce risk of insulin resistance: potential role for lipodystrophy
27 May 2014. Related: Other news.
SCART study: selumetinib as potential treatment for HIV-related KS
27 May 2014. Related: Other news.
Scotland agrees to free HIV treatment, regardless of residency status
27 May 2014. Related: Other news.
Volume 15 Number 5/6 May/June 2014 PDF
27 May 2014. Related: PDFs.
Community reports and briefings
27 May 2014. Related: On the web.
March/April 2014: Volume 15 Number 3/4
24 March 2014. Related: Editorial.
21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston
24 March 2014. Related: Conference reports.
No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up
24 March 2014. Related: Conference reports, HIV prevention and transmission.
PrEP injections every three months may protect against exposure from anal sex
24 March 2014. Related: Conference reports, HIV prevention and transmission.
ARV pipeline: doravirine, GSK-744 and BMS-068
24 March 2014. Related: Conference reports, Antiretrovirals.
Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pharmacokinetic targets for efavirenz might be too high
24 March 2014. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study
24 March 2014. Related: Conference reports, Side effects.
NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs
24 March 2014. Related: Conference reports, Treatment strategies, Drug resistance.
HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART
24 March 2014. Related: Conference reports, Pregnancy.
Lower newborn bone mineral content with maternal tenofovir use
24 March 2014. Related: Conference reports, Pregnancy.
Paediatric pipeline: CROI 2014 update on new antiretrovirals for children
24 March 2014. Related: Conference reports, Paediatric care.
Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis
24 March 2014. Related: Conference reports, Paediatric care.
Xpert TB test has important advantages but does not reduce morbidity
24 March 2014. Related: Conference reports, TB coinfection.
Reports of a second baby possibly cured of HIV: uncertainty remains
24 March 2014. Related: Conference reports, Cure-related research, Basic science and immunology.
Updates on SB728-T, a CCR5-targeting gene therapy
24 March 2014. Related: Conference reports, Cure-related research, Basic science and immunology.
FDA approvals of generic ARVS
24 March 2014. Related: Treatment access.
UK guidelines for HIV-related cancers (2014): published online
24 March 2014. Related: Guidelines, Cancer and HIV.
Draft BHIVA pregnancy guidelines (2014) online for comment
24 March 2014. Related: Guidelines.
Strong recommendations in WHO 2014 guidelines are often based on lower quality evidence than indicated in GRADE approach
24 March 2014. Related: Guidelines.
FDA approves raltegravir for children older than 4 weeks
24 March 2014. Related: Paediatric care.
The prognostic value of interleukin-6 and D-dimer levels in primary HIV infection
24 March 2014. Related: Basic science and immunology.
HIV reservoir: CD4 T stem cells may facilitate long-term persistence
24 March 2014. Related: Basic science and immunology.
Update published on the first Berlin patient
24 March 2014. Related: Basic science and immunology.
Poor CD4 T cell recovery despite HIV suppression linked to increased morbidity and mortality
24 March 2014. Related: Basic science and immunology.
The relevance of the CD4/CD8 ratio in the ART era
24 March 2014. Related: Basic science and immunology.
First human trial of AAV as a delivery vehicle for HIV neutralising antibodies gets underway
24 March 2014. Related: Basic science and immunology.
Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting
24 March 2014. Related: Hepatitis coinfection.
New treatments for HCV: strategies for achieving universal access
24 March 2014. Related: Hepatitis coinfection.
Conference resources
24 March 2014. Related: On the web.
Volume 15 Number 3/4 March/April 2014 PDF
24 March 2014. Related: PDFs.
Online articles
24 March 2014. Related: On the web.
Volume 15 Number 1/2 January/February 2014 PDF
1 February 2014. Related: PDFs.
January/February 2014: Volume 15 Number 1/2
1 February 2014. Related: Editorial.
4th International Workshop on HIV & Women, 13-14 January 2014, Washington
1 February 2014. Related: Conference reports.
Women, HIV research and antiretrovirals
1 February 2014. Related: Conference reports, Antiretrovirals, Women's health, Cure-related research.
Improved virological outcomes for women starting efavirenz-based first-line regimens in South Africa
1 February 2014. Related: Conference reports, Women's health.
High rates of pregnancy in HIV positive women in Zambia and South Africa
1 February 2014. Related: Conference reports, Women's health, Pregnancy.
Contraceptive choices among a Canadian cohort of HIV positive women
1 February 2014. Related: Conference reports, Women's health.
Bone disease and older HIV positive women
1 February 2014. Related: Conference reports, Women's health.
Lower immune response to the qHPV vaccine in HIV positive girls
1 February 2014. Related: Conference reports, Women's health, Paediatric care.
HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study
1 February 2014. Related: Conference reports, Pregnancy, Paediatric care.
Outcomes in infants exposed to lopinavir/ritonavir in utero
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
17th International Conference on AIDS and STIs in Africa (ICASA), 7-11 December 2013, Cape Town
1 February 2014. Related: Conference reports.
Two percent rate of efavirenz discontinuation in an ART programme in Malawi
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
6th International Workshop on HIV Persistence During Therapy, 3-6 December 2013, Miami, USA
1 February 2014. Related: Conference reports.
Report from the 6th Workshop on HIV Persistence
1 February 2014. Related: Conference reports, Cure-related research.
Dolutegravir approved in Europe
1 February 2014. Related: Antiretrovirals, Treatment access.
BMS to add atazanavir to Patent Pool
1 February 2014. Related: Treatment access.
Donors pledge $12 billion to Global Fund for 2014–2016: increase still short of $15 billion goal
1 February 2014. Related: Treatment access.
Global Fund and UNAIDS urge Nigeria to reconsider new anti-gay law
1 February 2014. Related: Treatment access.